Bristol Myers: EU approves cancer drugs
(CercleFinance.com) - Bristol Myers Squibb has received approval from the European Commission for Opdivo (nivolumab) and Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
Approval, based on the results of the phase 3 CheckMate -9DW clinical trial, demonstrated a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to the investigator's choice of lenvatinib or sorafenib.
The European Commission's approval of Opdivo plus Yervoy adds to the growing body of evidence demonstrating the value of dual immunotherapy and represents an important new treatment option that could prolong survival for patients with hepatocellular carcinoma, it said.
This approval marks a critical milestone in our commitment to improving outcomes for liver cancer patients. We look forward to bringing this new first-line treatment option to patients in the European Union.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
Approval, based on the results of the phase 3 CheckMate -9DW clinical trial, demonstrated a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to the investigator's choice of lenvatinib or sorafenib.
The European Commission's approval of Opdivo plus Yervoy adds to the growing body of evidence demonstrating the value of dual immunotherapy and represents an important new treatment option that could prolong survival for patients with hepatocellular carcinoma, it said.
This approval marks a critical milestone in our commitment to improving outcomes for liver cancer patients. We look forward to bringing this new first-line treatment option to patients in the European Union.
Copyright (c) 2025 CercleFinance.com. All rights reserved.